Moderate heart failure

This study tests a small sensor implanted in the lung artery that sends daily pressure readings to doctors. It involves 81 adults with advanced heart failure (NYHA Class III). The goal is to see if the device is safe and accurate, helping patients avoid hospital stays by catching…

This study tested a small sensor placed in the lung artery to help doctors monitor heart failure patients remotely. 738 people with advanced (NYHA Class III) heart failure took part. The goal was to see if using the sensor could reduce hospitalizations and deaths compared to a ta…

This study follows 2,500 people with moderate heart failure (NYHA Class II or III) who already have a CardioMEMS sensor implanted in their lung artery. The sensor wirelessly sends pressure readings to doctors, who use the data to adjust medications. Researchers will track surviva…

This study tests a one-time gene therapy called AB-1002, given directly into the heart arteries, for people with advanced heart failure (NYHA Class III). The goal is to see if it can improve heart function, reduce symptoms, and lower the risk of death or hospitalization. About 15…

This early study tests a device that creates a small, temporary opening in the wall of the heart to relieve pressure and improve symptoms in people with advanced heart failure. The main goal is to see if the procedure is safe. About 20 participants who have not responded well to …

This study looks at whether a quick, simple test—standing up and sitting down from a chair as many times as possible in one minute—can help predict how heart failure patients will fare after leaving the hospital. Researchers will follow 68 adults hospitalized for decompensated he…

This study looks at how SGLT2 inhibitors, a type of diabetes drug also used for heart failure, affect the body's metabolism. About 40 adults with mild to moderate heart failure will have blood tests, walking tests, and calf MRIs before and after starting the medication. The goal …